Switch theme
Sign up to access all valuation multiples
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
2014
403
LTM Revenue $57.0M
LTM EBITDA -$474M
$326M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Intellia Therapeutics has a last 12-month revenue (LTM) of $57.0M and a last 12-month EBITDA of -$474M.
In the most recent fiscal year, Intellia Therapeutics achieved revenue of $57.9M and an EBITDA of -$524M.
Intellia Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Intellia Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $57.0M | XXX | $57.9M | XXX | XXX | XXX |
| Gross Profit | $57.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$474M | XXX | -$524M | XXX | XXX | XXX |
| EBITDA Margin | -831% | XXX | -905% | XXX | XXX | XXX |
| EBIT | -$498M | XXX | -$534M | XXX | XXX | XXX |
| EBIT Margin | -873% | XXX | -923% | XXX | XXX | XXX |
| Net Profit | -$482M | XXX | -$519M | XXX | XXX | XXX |
| Net Margin | -847% | XXX | -897% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Intellia Therapeutics's stock price is $7.
Intellia Therapeutics has current market cap of $710M, and EV of $326M.
See Intellia Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $326M | $710M | XXX | XXX | XXX | XXX | $-4.82 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Intellia Therapeutics has market cap of $710M and EV of $326M.
Intellia Therapeutics's trades at 5.6x EV/Revenue multiple, and -0.6x EV/EBITDA.
Equity research analysts estimate Intellia Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Intellia Therapeutics has a P/E ratio of -1.5x.
See valuation multiples for Intellia Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $710M | XXX | $710M | XXX | XXX | XXX |
| EV (current) | $326M | XXX | $326M | XXX | XXX | XXX |
| EV/Revenue | 5.7x | XXX | 5.6x | XXX | XXX | XXX |
| EV/EBITDA | -0.7x | XXX | -0.6x | XXX | XXX | XXX |
| EV/EBIT | -0.7x | XXX | -0.6x | XXX | XXX | XXX |
| EV/Gross Profit | 5.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.5x | XXX | -1.4x | XXX | XXX | XXX |
| EV/FCF | -0.8x | XXX | -0.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIntellia Therapeutics's last 12 month revenue growth is -9%
Intellia Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.5M for the same period.
Intellia Therapeutics's rule of 40 is -1405% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Intellia Therapeutics's rule of X is -854% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Intellia Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -9% | XXX | -11% | XXX | XXX | XXX |
| EBITDA Margin | -831% | XXX | -905% | XXX | XXX | XXX |
| EBITDA Growth | -6% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1405% | XXX | -914% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -854% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 806% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1023% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Intellia Therapeutics acquired XXX companies to date.
Last acquisition by Intellia Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Intellia Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Intellia Therapeutics founded? | Intellia Therapeutics was founded in 2014. |
| Where is Intellia Therapeutics headquartered? | Intellia Therapeutics is headquartered in United States of America. |
| How many employees does Intellia Therapeutics have? | As of today, Intellia Therapeutics has 403 employees. |
| Who is the CEO of Intellia Therapeutics? | Intellia Therapeutics's CEO is Dr. John M. Leonard, M.D.. |
| Is Intellia Therapeutics publicy listed? | Yes, Intellia Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Intellia Therapeutics? | Intellia Therapeutics trades under NTLA ticker. |
| When did Intellia Therapeutics go public? | Intellia Therapeutics went public in 2016. |
| Who are competitors of Intellia Therapeutics? | Similar companies to Intellia Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Intellia Therapeutics? | Intellia Therapeutics's current market cap is $710M |
| What is the current revenue of Intellia Therapeutics? | Intellia Therapeutics's last 12 months revenue is $57.0M. |
| What is the current revenue growth of Intellia Therapeutics? | Intellia Therapeutics revenue growth (NTM/LTM) is -9%. |
| What is the current EV/Revenue multiple of Intellia Therapeutics? | Current revenue multiple of Intellia Therapeutics is 5.7x. |
| Is Intellia Therapeutics profitable? | Yes, Intellia Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Intellia Therapeutics? | Intellia Therapeutics's last 12 months EBITDA is -$474M. |
| What is Intellia Therapeutics's EBITDA margin? | Intellia Therapeutics's last 12 months EBITDA margin is -831%. |
| What is the current EV/EBITDA multiple of Intellia Therapeutics? | Current EBITDA multiple of Intellia Therapeutics is -0.7x. |
| What is the current FCF of Intellia Therapeutics? | Intellia Therapeutics's last 12 months FCF is -$411M. |
| What is Intellia Therapeutics's FCF margin? | Intellia Therapeutics's last 12 months FCF margin is -721%. |
| What is the current EV/FCF multiple of Intellia Therapeutics? | Current FCF multiple of Intellia Therapeutics is -0.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
